1
Return

Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial

delete2026-07-01
delete0
PRE
AI
H
Herui Yao
Q
Qingyuan Zhang
H
Huiping Li
Y
Yongmei Yin
S
Shusen Wang
Q
Quchang Ouyang
T
Tao Sun
W
Wei Li
X
Xiaojia Wang
M
Min Yan
B
Biyun Wang
J
Jing Cheng
Z
Zhongsheng Tong
W
Wei Wei
X
Xinshuai Wang
W
Weimin Xie
Z
Zhengkui Sun
P
Peng Yuan
C
Cuizhi Geng
L
Lu Gan
DOI：10.1016/S1470-2045(26)00193-2delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Trastuzumab rezetecan has shown antitumour activity in a phase 1 trial. Pyrotinib plus capecitabine is the current standard treatment for patients with HER2-positive advanced or metastatic breast cancer after trastuzumab and chemotherapy (taxane or anthracycline). We aimed to evaluate the efficacy and safety of trastuzumab rezetecan versus pyrotinib plus capecitabine in this patient population.

Journal

T
The Lancet Oncology
IF:
0
Papers:
348
Citations:
1

Organization

No organization information available
Cited Papers

Cited Papers

Citing Papers

Citing Papers